Global CDMO Recipharm has acquired Vibalogics, a virotherapy CDMO, expanding its biologics capabilities. The virotherapy company manufactures of oncolytic viruses, viral vaccines and gene therapies, while offering process and analytical development, manufacturing, testing and fill-finish services.
These services are aimed to meet growing industry demand for specialised CDMO capabilities for the manufacture of live viruses and viral vectors including herpes viruses, pox viruses, adenoviruses, and other viral classes for cancer and other applications. Continued investment, including a recent expansion in Germany and the US, has positioned the company to support the full product lifecycle for clients, it says.
This deal will provide Recipharm with capabilities in additional biologics modalities, building on the capabilities gained through the recently announced GenIbet transaction and the acquisition of Arranta Bio.
Marc Funk, CEO at Recipharm, said: “We are excited by the opportunities that are already apparent from working with true pioneers in the area of virotherapy manufacturing. We are delighted to welcome our new colleagues from Vibalogics to Recipharm and are committed to support and even accelerate growth in the years to come and to continue to partner with customers in virus manufacturing solutions. This acquisition strengthens Recipharm’s presence in ATMPs and enables us to get closer to our US customers. We look forward to working with the Vibalogics team, building links across the wider Recipharm organisation to make this business a huge success.”
Tom Hochuli, CEO at Vibalogics, added: “Since 2006 Vibalogics has developed a specialised CDMO business and a leading virotherapy manufacturing platform that has contributed to advancing our customers’ products through development and into global clinical trials, all made possible by our dedicated employees and investors. We are excited to be joining the Recipharm organisation and having the opportunity to leverage the breadth and depth of its world leading infrastructure and experience. This furthers our commitment to supporting our customers and the patients who benefit from the exciting developments we are witnessing in the virotherapy field.”